JP Morgan Maintains Overweight on Solid Biosciences, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 88.7%

Neg 0% Neu 0% Pos 88.7%

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $11 to $12.